Status:
COMPLETED
The "Metabolically-obese Normal-weight" Phenotype and Its Reversal by Calorie Restriction
Lead Sponsor:
Singapore Institute of Food and Biotechnology Innovation
Conditions:
Glucose Metabolism Disorders
Obesity, Visceral
Eligibility:
All Genders
21-65 years
Phase:
NA
Brief Summary
The prevalence of overweight and obesity in Singapore is approximately half of that in the United States, yet the incidence of type 2 diabetes is similar, and is expected to double in the near future....
Detailed Description
By the year 2050, it is estimated that more than half of the Singapore population will be overweight or obese, defined as having a body mass index (BMI, calculated as the weight in kilograms divided b...
Eligibility Criteria
Inclusion
- Healthy male or female
- Chinese or Indian descent
- Between 21-65 years old (inclusive)
- BMI from \>=19 to \<25 kg/m2
Exclusion
- BMI ≥25 kg/m2
- BMI \<19 kg/m2 (to avoid the risk of subjects becoming seriously underweight (i.e. BMI ≤18 kg/m2) after 5 % weight loss)
- Age \<21 and \>65 yrs
- Use of medications that can affect metabolic function (including oral contraceptives and hormone replacement therapy)
- Regular use of tobacco products
- Regular consumption of alcohol
- Pregnant or breastfeeding women
- Evidence of significant organ system dysfunction or disease
- Recent weight loss (≥5 % over the past 6 months)
- Severe asthma and respiratory problems that prevent subjects from exercising
Key Trial Info
Start Date :
March 29 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 7 2017
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT03239782
Start Date
March 29 2016
End Date
October 7 2017
Last Update
March 13 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.